Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of primary cytoreductive surgery with or without HIPEC in stage III epithelial ovarian cancer
2018-003346-17Phase 3Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin in epithelial ovarian cancer (EOC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: overall survival. Started Apr 2019; status: active.
02
Drugs
cisplatin
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2018-003346-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003346-17.